Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Bullboard Posts
Comment by billy4325on Sep 27, 2018 3:45pm
65 Views
Post# 28703711

RE:RE:RE:RE:Alternative forms of energy beverages

RE:RE:RE:RE:Alternative forms of energy beveragesThe company can say whatever it wants, doesn't mean it is reality.  In the 2nd half of 2016, they expected the cholesterol clinical trial to start in Q4 2016.  They also expected to complete the transfer of all manufacturing operations by the first quarter 2017 to the new facility.  Here we are nearing the end of 2018 without the trial started and still running both plants.  It's pretty clear that their timelines and expectations aren't any use for realistic expectations of what or when events will happen in the future.

digitel wrote:
"But here we sit at a .35 cent share price wondering what happened to Ceapro and all its talked up potential. Once again i share the frustration."

We are waiting for binary events. If they happen they happen. If it a deal happens, for instance, you will wake up one morning and could be very surprised at the sudden interest. CZO said it will partner with a "multinational" on the CoQ10 drink three months ago in a news release. Early in the year it said companies were "extremely, extremely" interested. It has said it continues to be very excited. The presentation on the website says partnering and sales are next. The news release said the CoQ10 drink is available for license in certain territories. Time will tell...

CZO Website:

"CoQ10 was selected in this new complex because it is an essential compound required for basic cell function in human and, when adequately absorbed by the body, it can alleviate the onset of severe diseases. Indeed, CoQ10 maintains the integrity of mitochondria thereby helping to convert food into energy while also acting as an antioxidant. The human body contains an estimated amount of 2000 mg of CoQ10, of which 500 mg must be replenished daily, especially after the age of 20 when the CoQ10 content of human organs decreases substantially1. Given that average dietary intake of CoQ10 was estimated as 3-6 mg/day with meat being the major source, supplementation using a bioavailable supplement is required to achieve the recommended daily intake of 30-100 mg for healthy people and 60-1200 mg for individuals with certain medical conditions1, including those taking statin medication which are known to reduce CoQ10 biosynthesis2. CoQ10 deficiency leads to a number of ailments such as: fatal cardiomyopathy, heart attack, congestive heart failure, cancer, myopathy, exhaustion, depression, high blood pressure, gum disease, hair loss, liver disease, memory loss or amnesia, cataracts, angina, folic acid deficiency, and damaged cell membranes2."

1. Pravst I., Zmitek K., Zmitek J., Coenzyme Q10 contents in foods and fortification strategies, Crit Rev Food Sci Nutr 2010, 50:269-280
2. Grisanti R., The CoQ10-Statin Secret, Functional Medicine University, 2018, https://www.functionalmedicineuniversity.com/public/883.cfm


Read more at https://www.stockhouse.com/companies/bullboard?symbol=v.czo&postid=28659125#Mk3JufSAYTFOZYp5.99
 



Bullboard Posts